These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 20384464)

  • 1. Oral complications associated with D-penicillamine treatment for Wilson disease: a clinicopathologic report.
    Tovaru S; Parlatescu I; Dumitriu AS; Bucur A; Kaplan I
    J Periodontol; 2010 Aug; 81(8):1231-6. PubMed ID: 20384464
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of oral chelators in treatment of patients with Wilson disease.
    Weiss KH; Thurik F; Gotthardt DN; Schäfer M; Teufel U; Wiegand F; Merle U; Ferenci-Foerster D; Maieron A; Stauber R; Zoller H; Schmidt HH; Reuner U; Hefter H; Trocello JM; Houwen RH; Ferenci P; Stremmel W;
    Clin Gastroenterol Hepatol; 2013 Aug; 11(8):1028-35.e1-2. PubMed ID: 23542331
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Elastosis perforans serpiginosa associated with pseudo-pseudoxanthoma elasticum during treatment of Wilson's disease with penicillamine.
    Bécuwe C; Dalle S; Ronger-Savlé S; Skowron F; Balme B; Kanitakis J; Thomas L
    Dermatology; 2005; 210(1):60-3. PubMed ID: 15604549
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Penicillamine-induced elastosis perforans serpiginosa with abnormal "lumpy-bumpy" elastic fibers in lesional and non-lesional skin.
    Khatu SS; Dhurat RS; Nayak CS; Pereira RR; Kagne RB
    Indian J Dermatol Venereol Leprol; 2011; 77(1):55-8. PubMed ID: 21220881
    [TBL] [Abstract][Full Text] [Related]  

  • 5. D-penicillamine elastosis perforans serpiginosa: description of two cases and review of the literature.
    Atzori L; Pinna AL; Pau M; Aste N
    Dermatol Online J; 2011 Apr; 17(4):3. PubMed ID: 21549078
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Elastosis perforans serpiginosa induced by penicillamine.
    Kirsch N; Hukill PB
    Arch Dermatol; 1977 May; 113(5):630-5. PubMed ID: 857731
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Wilson's disease: long-term follow-up of a cohort of 24 patients treated with D-penicillamine.
    Lowette KF; Desmet K; Witters P; Laleman W; Verslype C; Nevens F; Fevery J; Cassiman DM
    Eur J Gastroenterol Hepatol; 2010 May; 22(5):564-71. PubMed ID: 20042865
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Penicillamine-induced elastosis of the mucosal lip.
    Lewis BK; Chern PL; Stone MS
    J Am Acad Dermatol; 2009 Apr; 60(4):700-3. PubMed ID: 19293020
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Elastosis perforans serpiginosa secondary to D-penicillamine therapy with coexisting cutis laxa.
    Rosen LB; Muellenhoff M; Tran TT; Muhart M
    Cutis; 2005 Jul; 76(1):49-53. PubMed ID: 16144289
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Penicillamine-induced degenerative dermatoses: report of a case and brief review of such dermatoses.
    Iozumi K; Nakagawa H; Tamaki K
    J Dermatol; 1997 Jul; 24(7):458-65. PubMed ID: 9267106
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Penicillamine-induced elastosis perforans serpiginosa and pulmonary cyst in Wilson's disease (author's transl)].
    Bardach H; Gebhart W; Niebauer G; Bardach G
    Wien Klin Wochenschr; 1981 Feb; 93(4):117-22. PubMed ID: 7281683
    [TBL] [Abstract][Full Text] [Related]  

  • 12. D-penicillamine-induced elastosis perforans serpiginosa and localized cutis laxa in a patient with Wilson's disease.
    Amichai B; Rotem A; Metzker A
    Isr J Med Sci; 1994 Aug; 30(8):667-9. PubMed ID: 8045756
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Worsening of Wilson disease following penicillamine therapy.
    Kalita J; Kumar V; Chandra S; Kumar B; Misra UK
    Eur Neurol; 2014; 71(3-4):126-31. PubMed ID: 24356057
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discontinuation of penicillamine in the absence of alternative orphan drugs (trientine-zinc): a case of decompensated liver cirrhosis in Wilson's disease.
    Ping CC; Hassan Y; Aziz NA; Ghazali R; Awaisu A
    J Clin Pharm Ther; 2007 Feb; 32(1):101-7. PubMed ID: 17286794
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Elastosis perforans serpiginosa: causes and associated disorders.
    Montesu MA; Onnis G; Gunnella S; Lissia A; Satta R
    Eur J Dermatol; 2018 Aug; 28(4):476-481. PubMed ID: 30129530
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Switching Pharmacological Treatment in Wilson Disease: Case Report and Recommendations.
    Leung M; Wu Lanzafame J; Medici V
    J Investig Med High Impact Case Rep; 2020; 8():2324709619896876. PubMed ID: 31920114
    [No Abstract]   [Full Text] [Related]  

  • 17. Dermoscopy and direct immunofluorescence findings of elastosis perforans serpiginosa.
    Ramírez-Bellver JL; Bernárdez C; Macías E; Moya L; Molina-Ruiz AM; Cannata Ortiz P; Requena L
    Clin Exp Dermatol; 2016 Aug; 41(6):667-70. PubMed ID: 27378586
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative effectiveness of common therapies for Wilson disease: A systematic review and meta-analysis of controlled studies.
    Appenzeller-Herzog C; Mathes T; Heeres MLS; Weiss KH; Houwen RHJ; Ewald H
    Liver Int; 2019 Nov; 39(11):2136-2152. PubMed ID: 31206982
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The "lumpy-bumpy" elastic fiber. A marker for long-term administration of penicillamine.
    Gebhart W; Bardach H
    Am J Dermatopathol; 1981; 3(1):33-9. PubMed ID: 7235197
    [TBL] [Abstract][Full Text] [Related]  

  • 20. D-Penicillamine-induced ANCA-associated crescentic glomerulonephritis in Wilson disease.
    Bienaimé F; Clerbaux G; Plaisier E; Mougenot B; Ronco P; Rougier JP
    Am J Kidney Dis; 2007 Nov; 50(5):821-5. PubMed ID: 17954295
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.